BridgeBio Pharma Statistics
Total Valuation
BBIO has a market cap or net worth of $9.94 billion. The enterprise value is $10.99 billion.
Important Dates
The last earnings date was Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BBIO has 191.17 million shares outstanding. The number of shares has increased by 7.74% in one year.
| Current Share Class | 191.17M |
| Shares Outstanding | 191.17M |
| Shares Change (YoY) | +7.74% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 4.63% |
| Owned by Institutions (%) | 83.25% |
| Float | 151.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 42.28 |
| Forward PS | 17.50 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 46.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.19
| Current Ratio | 5.19 |
| Quick Ratio | 4.74 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.74 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -41.96% |
| Return on Invested Capital (ROIC) | -108.17% |
| Return on Capital Employed (ROCE) | -69.58% |
| Revenue Per Employee | $323,030 |
| Profits Per Employee | -$1.06M |
| Employee Count | 730 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BBIO has paid $3.25 million in taxes.
| Income Tax | 3.25M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +111.93% in the last 52 weeks. The beta is 1.23, so BBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +111.93% |
| 50-Day Moving Average | 46.81 |
| 200-Day Moving Average | 36.19 |
| Relative Strength Index (RSI) | 65.03 |
| Average Volume (20 Days) | 2,890,579 |
Short Selling Information
The latest short interest is 20.49 million, so 10.72% of the outstanding shares have been sold short.
| Short Interest | 20.49M |
| Short Previous Month | 18.52M |
| Short % of Shares Out | 10.72% |
| Short % of Float | 13.54% |
| Short Ratio (days to cover) | 7.36 |
Income Statement
In the last 12 months, BBIO had revenue of $235.81 million and -$776.42 million in losses. Loss per share was -$4.09.
| Revenue | 235.81M |
| Gross Profit | 226.84M |
| Operating Income | -629.24M |
| Pretax Income | -453.82M |
| Net Income | -776.42M |
| EBITDA | -623.73M |
| EBIT | -629.24M |
| Loss Per Share | -$4.09 |
Full Income StatementBalance Sheet
The company has $756.89 million in cash and $1.86 billion in debt, giving a net cash position of -$1.10 billion or -$5.76 per share.
| Cash & Cash Equivalents | 756.89M |
| Total Debt | 1.86B |
| Net Cash | -1.10B |
| Net Cash Per Share | -$5.76 |
| Equity (Book Value) | -1.78B |
| Book Value Per Share | -9.35 |
| Working Capital | 736.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$655.81 million and capital expenditures -$778,000, giving a free cash flow of -$656.59 million.
| Operating Cash Flow | -655.81M |
| Capital Expenditures | -778,000 |
| Free Cash Flow | -656.59M |
| FCF Per Share | -$3.43 |
Full Cash Flow StatementMargins
| Gross Margin | 96.19% |
| Operating Margin | -266.84% |
| Pretax Margin | -331.52% |
| Profit Margin | n/a |
| EBITDA Margin | -264.50% |
| EBIT Margin | -266.84% |
| FCF Margin | n/a |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.74% |
| Shareholder Yield | -7.74% |
| Earnings Yield | -7.85% |
| FCF Yield | -6.64% |
Dividend DetailsAnalyst Forecast
The average price target for BBIO is $61.69, which is 18.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $61.69 |
| Price Target Difference | 18.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 65.26% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BBIO has an Altman Z-Score of -4.14 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.14 |
| Piotroski F-Score | 2 |
